The terms, per the grant. On January 26, 2021, Agilent Technologies was issued US10900034B2, "Guide RNA with chemical modifications." The dense CPC stack — C12N 15/111, plus a long series of C12N 2310 modification tags (2310/321, 2310/322, 2310/3231 and more) — describes the specific chemistry that makes a guide RNA stable and effective enough to use therapeutically.
Why a deals desk separates this layer: in gene editing, the drug companies make the medicines, but the reagent and tooling suppliers own IP that the drug companies must use or license. Chemically modified guides are a classic picks-and-shovels asset — value that accrues to a supplier through reagent sales and licensing rather than through any single clinical program.
The structure point: tooling IP supports a fundamentally different royalty than drug IP. It can collect a small, broad royalty across the whole field, insulated from any one program's clinical risk. For a teardown, that is a more diversified, lower-variance value stream than a single-asset royalty.
What the grant does not promise: a clinical result or a marketed product — that is not what tooling IP is for. It is an exclusivity claim on a chemistry, and its value depends on how widely that chemistry is used across the field.
The takeaway: when tearing down gene-editing economics, do not stop at the drug grants — read the reagent and modified-guide IP, because that is where broad, program-agnostic royalties live. Agilent's January 2021 modified-guide grant is a dated example of the tooling layer.